KR20180122484A - 세포-지지체 구조물 - Google Patents
세포-지지체 구조물 Download PDFInfo
- Publication number
- KR20180122484A KR20180122484A KR1020187031781A KR20187031781A KR20180122484A KR 20180122484 A KR20180122484 A KR 20180122484A KR 1020187031781 A KR1020187031781 A KR 1020187031781A KR 20187031781 A KR20187031781 A KR 20187031781A KR 20180122484 A KR20180122484 A KR 20180122484A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- bladder
- tissue
- smooth muscle
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000003815 abdominal wall Anatomy 0.000 claims description 39
- 230000002950 deficient Effects 0.000 claims description 25
- 210000003708 urethra Anatomy 0.000 claims description 14
- 210000000056 organ Anatomy 0.000 abstract description 153
- 230000008929 regeneration Effects 0.000 abstract description 75
- 238000011069 regeneration method Methods 0.000 abstract description 75
- 230000003416 augmentation Effects 0.000 abstract description 36
- 230000008707 rearrangement Effects 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 503
- 210000004027 cell Anatomy 0.000 description 464
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 334
- 210000001519 tissue Anatomy 0.000 description 261
- 210000003932 urinary bladder Anatomy 0.000 description 247
- 239000011159 matrix material Substances 0.000 description 204
- 238000000034 method Methods 0.000 description 196
- 238000002513 implantation Methods 0.000 description 118
- 210000000626 ureter Anatomy 0.000 description 109
- 238000012360 testing method Methods 0.000 description 102
- 230000014509 gene expression Effects 0.000 description 97
- 229920000642 polymer Polymers 0.000 description 96
- 210000001635 urinary tract Anatomy 0.000 description 89
- 210000002700 urine Anatomy 0.000 description 84
- 239000008280 blood Substances 0.000 description 80
- 210000004369 blood Anatomy 0.000 description 79
- 210000000577 adipose tissue Anatomy 0.000 description 76
- 230000002485 urinary effect Effects 0.000 description 75
- 239000000523 sample Substances 0.000 description 64
- 238000011282 treatment Methods 0.000 description 64
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 63
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 63
- 210000002460 smooth muscle Anatomy 0.000 description 62
- 239000000463 material Substances 0.000 description 57
- 210000003734 kidney Anatomy 0.000 description 56
- 239000011886 peripheral blood Substances 0.000 description 55
- 210000005259 peripheral blood Anatomy 0.000 description 54
- 210000002837 heart atrium Anatomy 0.000 description 52
- 108090000623 proteins and genes Proteins 0.000 description 50
- 210000003491 skin Anatomy 0.000 description 50
- 238000002054 transplantation Methods 0.000 description 50
- 238000001356 surgical procedure Methods 0.000 description 46
- 238000001574 biopsy Methods 0.000 description 43
- 230000003187 abdominal effect Effects 0.000 description 42
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 39
- 239000007943 implant Substances 0.000 description 38
- 241001673669 Porcine circovirus 2 Species 0.000 description 37
- 230000015572 biosynthetic process Effects 0.000 description 37
- 210000004303 peritoneum Anatomy 0.000 description 36
- 230000008439 repair process Effects 0.000 description 36
- 210000003205 muscle Anatomy 0.000 description 35
- 230000034994 death Effects 0.000 description 34
- 231100000517 death Toxicity 0.000 description 34
- 238000011887 Necropsy Methods 0.000 description 33
- 238000000151 deposition Methods 0.000 description 33
- 230000035876 healing Effects 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 32
- 238000012258 culturing Methods 0.000 description 31
- 108010035532 Collagen Proteins 0.000 description 30
- 102000008186 Collagen Human genes 0.000 description 30
- 229920001436 collagen Polymers 0.000 description 30
- 230000003890 fistula Effects 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 30
- 238000010899 nucleation Methods 0.000 description 29
- 206010016717 Fistula Diseases 0.000 description 28
- 230000008828 contractile function Effects 0.000 description 27
- 210000000683 abdominal cavity Anatomy 0.000 description 26
- 239000010410 layer Substances 0.000 description 26
- 239000003550 marker Substances 0.000 description 25
- 239000002609 medium Substances 0.000 description 25
- 239000011148 porous material Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 229920000954 Polyglycolide Polymers 0.000 description 23
- 238000011888 autopsy Methods 0.000 description 23
- 239000000306 component Substances 0.000 description 23
- 230000001965 increasing effect Effects 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 23
- 210000003741 urothelium Anatomy 0.000 description 23
- 230000006870 function Effects 0.000 description 21
- 239000012528 membrane Substances 0.000 description 21
- 239000004633 polyglycolic acid Substances 0.000 description 21
- 239000003102 growth factor Substances 0.000 description 20
- 210000004379 membrane Anatomy 0.000 description 20
- -1 polytetrafluoroethylene Polymers 0.000 description 20
- 230000002980 postoperative effect Effects 0.000 description 20
- 230000001172 regenerating effect Effects 0.000 description 20
- 230000017423 tissue regeneration Effects 0.000 description 20
- 230000002792 vascular Effects 0.000 description 20
- 230000001351 cycling effect Effects 0.000 description 19
- 238000011156 evaluation Methods 0.000 description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 18
- 108090000695 Cytokines Proteins 0.000 description 18
- 206010021639 Incontinence Diseases 0.000 description 18
- 238000010171 animal model Methods 0.000 description 18
- 239000011575 calcium Substances 0.000 description 18
- 229910052791 calcium Inorganic materials 0.000 description 18
- 238000011161 development Methods 0.000 description 18
- 230000018109 developmental process Effects 0.000 description 18
- 230000012010 growth Effects 0.000 description 18
- 210000004072 lung Anatomy 0.000 description 18
- 238000004393 prognosis Methods 0.000 description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 17
- 206010061218 Inflammation Diseases 0.000 description 17
- 238000009825 accumulation Methods 0.000 description 17
- 230000001413 cellular effect Effects 0.000 description 17
- 239000012091 fetal bovine serum Substances 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 17
- 230000004054 inflammatory process Effects 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 230000004083 survival effect Effects 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 230000001419 dependent effect Effects 0.000 description 16
- 210000004877 mucosa Anatomy 0.000 description 16
- 229920005615 natural polymer Polymers 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 229920001059 synthetic polymer Polymers 0.000 description 16
- 230000009385 viral infection Effects 0.000 description 16
- 102000006783 calponin Human genes 0.000 description 15
- 108010086826 calponin Proteins 0.000 description 15
- 239000006143 cell culture medium Substances 0.000 description 15
- 238000003384 imaging method Methods 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 210000000130 stem cell Anatomy 0.000 description 15
- 238000002604 ultrasonography Methods 0.000 description 15
- 229920001577 copolymer Polymers 0.000 description 14
- 210000004748 cultured cell Anatomy 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 14
- 102000007469 Actins Human genes 0.000 description 13
- 108010085238 Actins Proteins 0.000 description 13
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 13
- 102100031013 Transgelin Human genes 0.000 description 13
- 208000036142 Viral infection Diseases 0.000 description 13
- 210000001015 abdomen Anatomy 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 210000001185 bone marrow Anatomy 0.000 description 13
- 238000004891 communication Methods 0.000 description 13
- 230000008602 contraction Effects 0.000 description 13
- 230000007170 pathology Effects 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 13
- 102000029816 Collagenase Human genes 0.000 description 12
- 108060005980 Collagenase Proteins 0.000 description 12
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 12
- 241000282898 Sus scrofa Species 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 229960002424 collagenase Drugs 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000000981 epithelium Anatomy 0.000 description 12
- 210000003608 fece Anatomy 0.000 description 12
- 239000000835 fiber Substances 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 210000001789 adipocyte Anatomy 0.000 description 11
- 239000002771 cell marker Substances 0.000 description 11
- 210000002808 connective tissue Anatomy 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 230000008021 deposition Effects 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000003414 extremity Anatomy 0.000 description 11
- 230000002550 fecal effect Effects 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- 210000000936 intestine Anatomy 0.000 description 11
- 210000001165 lymph node Anatomy 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 10
- 241000282887 Suidae Species 0.000 description 10
- 230000029142 excretion Effects 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 210000000651 myofibroblast Anatomy 0.000 description 10
- 230000007704 transition Effects 0.000 description 10
- 230000003442 weekly effect Effects 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 206010020524 Hydronephrosis Diseases 0.000 description 9
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 9
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000000560 biocompatible material Substances 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 239000013068 control sample Substances 0.000 description 9
- 239000003599 detergent Substances 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108010025714 CD146 Antigen Proteins 0.000 description 8
- 241000282465 Canis Species 0.000 description 8
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 8
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 8
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 8
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 8
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 8
- 101150044441 PECAM1 gene Proteins 0.000 description 8
- 108010001267 Protein Subunits Proteins 0.000 description 8
- 102100025368 Runt-related transcription factor 2 Human genes 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 206010046543 Urinary incontinence Diseases 0.000 description 8
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 8
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 8
- 230000003872 anastomosis Effects 0.000 description 8
- 230000003190 augmentative effect Effects 0.000 description 8
- 239000012620 biological material Substances 0.000 description 8
- 230000015271 coagulation Effects 0.000 description 8
- 238000005345 coagulation Methods 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 230000013632 homeostatic process Effects 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 244000309715 mini pig Species 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 210000000663 muscle cell Anatomy 0.000 description 8
- 239000013610 patient sample Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 210000005070 sphincter Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 201000002327 urinary tract obstruction Diseases 0.000 description 8
- 108010047303 von Willebrand Factor Proteins 0.000 description 8
- 102100036537 von Willebrand factor Human genes 0.000 description 8
- 229960001134 von willebrand factor Drugs 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102100032912 CD44 antigen Human genes 0.000 description 7
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 7
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 7
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 7
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 7
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 7
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 7
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 7
- 102100039065 Interleukin-1 beta Human genes 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 102000004264 Osteopontin Human genes 0.000 description 7
- 108010081689 Osteopontin Proteins 0.000 description 7
- 206010037596 Pyelonephritis Diseases 0.000 description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 7
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 7
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 210000005068 bladder tissue Anatomy 0.000 description 7
- 238000002659 cell therapy Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000002562 urinalysis Methods 0.000 description 7
- 206010000050 Abdominal adhesions Diseases 0.000 description 6
- 206010005003 Bladder cancer Diseases 0.000 description 6
- 206010015548 Euthanasia Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000006866 deterioration Effects 0.000 description 6
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 6
- 210000003195 fascia Anatomy 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 238000012735 histological processing Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 210000004731 jugular vein Anatomy 0.000 description 6
- 238000002357 laparoscopic surgery Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000000713 mesentery Anatomy 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 230000001338 necrotic effect Effects 0.000 description 6
- 230000002956 necrotizing effect Effects 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 208000023504 respiratory system disease Diseases 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 201000005112 urinary bladder cancer Diseases 0.000 description 6
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- 239000002251 absorbable suture material Substances 0.000 description 5
- 210000003484 anatomy Anatomy 0.000 description 5
- 208000022531 anorexia Diseases 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000030944 contact inhibition Effects 0.000 description 5
- 238000009799 cystectomy Methods 0.000 description 5
- 206010061428 decreased appetite Diseases 0.000 description 5
- 230000010339 dilation Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 230000009023 proprioceptive sensation Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 230000009772 tissue formation Effects 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 108030001720 Bontoxilysin Proteins 0.000 description 4
- 102100027951 Brain and acute leukemia cytoplasmic protein Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 102100036912 Desmin Human genes 0.000 description 4
- 108010044052 Desmin Proteins 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010013554 Diverticulum Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 101000697853 Homo sapiens Brain and acute leukemia cytoplasmic protein Proteins 0.000 description 4
- 208000008081 Intestinal Fistula Diseases 0.000 description 4
- 229920001410 Microfiber Polymers 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000003505 Myosin Human genes 0.000 description 4
- 108060008487 Myosin Proteins 0.000 description 4
- 208000035965 Postoperative Complications Diseases 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 102000002067 Protein Subunits Human genes 0.000 description 4
- 206010038540 Renal tubular necrosis Diseases 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 4
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 210000004504 adult stem cell Anatomy 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 238000006065 biodegradation reaction Methods 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 229940053031 botulinum toxin Drugs 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 210000005045 desmin Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001839 endoscopy Methods 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000001497 fibrovascular Effects 0.000 description 4
- 238000002594 fluoroscopy Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 238000007489 histopathology method Methods 0.000 description 4
- 238000007443 liposuction Methods 0.000 description 4
- 239000003658 microfiber Substances 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000003660 reticulum Anatomy 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 4
- 238000012285 ultrasound imaging Methods 0.000 description 4
- 206010046494 urge incontinence Diseases 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 206010020853 Hypertonic bladder Diseases 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 3
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 239000012670 alkaline solution Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 238000002574 cystoscopy Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000000254 damaging effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 208000020629 overactive bladder Diseases 0.000 description 3
- 210000000505 parietal peritoneum Anatomy 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 238000013310 pig model Methods 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 238000009801 radical cystectomy Methods 0.000 description 3
- 238000011472 radical prostatectomy Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 230000016160 smooth muscle contraction Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 210000004003 subcutaneous fat Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000004876 tela submucosa Anatomy 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 238000009966 trimming Methods 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 230000009452 underexpressoin Effects 0.000 description 3
- 230000036325 urinary excretion Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000001720 vestibular Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 210000002417 xiphoid bone Anatomy 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 206010011906 Death Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 241001082241 Lythrum hyssopifolia Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010081823 Myocardin Proteins 0.000 description 2
- 102100030217 Myocardin Human genes 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 2
- 206010029279 Neurogenic bladder Diseases 0.000 description 2
- 206010061876 Obstruction Diseases 0.000 description 2
- 206010034238 Pelvic adhesions Diseases 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 239000004792 Prolene Substances 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 102100030859 Tissue factor Human genes 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 206010046404 Ureteric fistula Diseases 0.000 description 2
- 206010065809 Ureteric perforation Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000011759 adipose tissue development Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 210000001736 capillary Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000000555 contractile cell Anatomy 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000023753 dehiscence Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000009274 differential gene expression Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000001700 effect on tissue Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000023185 monocyte chemotactic protein-1 production Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000001002 morphogenetic effect Effects 0.000 description 2
- 210000003130 muscle precursor cell Anatomy 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000000807 solvent casting Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 208000022170 stress incontinence Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000003356 suture material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003106 tissue adhesive Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000004926 tubular epithelial cell Anatomy 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- 230000003966 vascular damage Effects 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- HEGSGKPQLMEBJL-RQICVUQASA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol Chemical compound CCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RQICVUQASA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 102100031786 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101100243025 Arabidopsis thaliana PCO2 gene Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000002880 Bladder exstrophy Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102000004497 CCR2 Receptors Human genes 0.000 description 1
- 108010017312 CCR2 Receptors Proteins 0.000 description 1
- 102100024210 CD166 antigen Human genes 0.000 description 1
- 101150093802 CXCL1 gene Proteins 0.000 description 1
- 102100029761 Cadherin-5 Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229920013683 Celanese Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 206010014172 Ectopic ureter Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 206010053236 Mixed incontinence Diseases 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004962 Polyamide-imide Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004697 Polyetherimide Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004734 Polyphenylene sulfide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010058046 Post procedural complication Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 101710102802 Runt-related transcription factor 2 Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 229920013808 TRITON DF-16 Polymers 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- 229920004896 Triton X-405 Polymers 0.000 description 1
- 229920004898 Triton X-705 Polymers 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 206010046479 Urethral valves Diseases 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047363 Vesical fistula Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000276425 Xiphophorus maculatus Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000003626 afferent pathway Anatomy 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000003443 bladder cell Anatomy 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 108010018828 cadherin 5 Proteins 0.000 description 1
- 239000003715 calcium chelating agent Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
- 229960002777 dicycloverine Drugs 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001643 poly(ether ketone) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002312 polyamide-imide Polymers 0.000 description 1
- 229920002577 polybenzoxazole Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- ODGAOXROABLFNM-UHFFFAOYSA-N polynoxylin Chemical compound O=C.NC(N)=O ODGAOXROABLFNM-UHFFFAOYSA-N 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920006380 polyphenylene oxide Polymers 0.000 description 1
- 229920000069 polyphenylene sulfide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 229920006295 polythiol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000272 proprioceptive effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 201000004537 pyelitis Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 210000002163 scaffold cell Anatomy 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 102000027509 sensory receptors Human genes 0.000 description 1
- 108091008691 sensory receptors Proteins 0.000 description 1
- 210000002151 serous membrane Anatomy 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- 239000000050 smooth muscle relaxant Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000003202 urodynamic effect Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000010066 viral adhesion Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/042—Urinary bladders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3826—Muscle cells, e.g. smooth muscle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3882—Hollow organs, e.g. bladder, esophagus, urether, uterus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/22—Materials or treatment for tissue regeneration for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials Engineering (AREA)
- Composite Materials (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11124208P | 2008-11-04 | 2008-11-04 | |
| US61/111,242 | 2008-11-04 | ||
| US11354208P | 2008-11-11 | 2008-11-11 | |
| US61/113,542 | 2008-11-11 | ||
| US11402108P | 2008-11-12 | 2008-11-12 | |
| US61/114,021 | 2008-11-12 | ||
| US11438808P | 2008-11-13 | 2008-11-13 | |
| US11438208P | 2008-11-13 | 2008-11-13 | |
| US61/114,388 | 2008-11-13 | ||
| US61/114,382 | 2008-11-13 | ||
| US20155508P | 2008-12-10 | 2008-12-10 | |
| US20155408P | 2008-12-10 | 2008-12-10 | |
| US20155008P | 2008-12-10 | 2008-12-10 | |
| US61/201,554 | 2008-12-10 | ||
| US61/201,555 | 2008-12-10 | ||
| US61/201,550 | 2008-12-10 | ||
| PCT/US2009/063306 WO2010054013A2 (en) | 2008-11-04 | 2009-11-04 | Cell-scaffold constructs |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187008826A Division KR20180034707A (ko) | 2008-11-04 | 2009-11-04 | 세포-지지체 구조물 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197016239A Division KR20190067267A (ko) | 2008-11-04 | 2009-11-04 | 세포-지지체 구조물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180122484A true KR20180122484A (ko) | 2018-11-12 |
Family
ID=41600400
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187031781A Ceased KR20180122484A (ko) | 2008-11-04 | 2009-11-04 | 세포-지지체 구조물 |
| KR1020117012781A Expired - Fee Related KR101724639B1 (ko) | 2008-11-04 | 2009-11-04 | 세포-지지체 구조물 |
| KR1020197016239A Ceased KR20190067267A (ko) | 2008-11-04 | 2009-11-04 | 세포-지지체 구조물 |
| KR1020177009069A Ceased KR20170041279A (ko) | 2008-11-04 | 2009-11-04 | 세포-지지체 구조물 |
| KR1020187008826A Ceased KR20180034707A (ko) | 2008-11-04 | 2009-11-04 | 세포-지지체 구조물 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117012781A Expired - Fee Related KR101724639B1 (ko) | 2008-11-04 | 2009-11-04 | 세포-지지체 구조물 |
| KR1020197016239A Ceased KR20190067267A (ko) | 2008-11-04 | 2009-11-04 | 세포-지지체 구조물 |
| KR1020177009069A Ceased KR20170041279A (ko) | 2008-11-04 | 2009-11-04 | 세포-지지체 구조물 |
| KR1020187008826A Ceased KR20180034707A (ko) | 2008-11-04 | 2009-11-04 | 세포-지지체 구조물 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8337485B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3461507A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6124041B2 (cg-RX-API-DMAC7.html) |
| KR (5) | KR20180122484A (cg-RX-API-DMAC7.html) |
| CN (2) | CN104274256A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009313554B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2742599A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2689932T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1205923A1 (cg-RX-API-DMAC7.html) |
| NZ (3) | NZ593208A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2352529T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2352529T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010054013A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020045260A1 (en) * | 2000-10-17 | 2002-04-18 | Shih-Chieh Hung | Method of isolating mesenchymal stem cells |
| US10022558B1 (en) | 2008-01-07 | 2018-07-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US9056201B1 (en) | 2008-01-07 | 2015-06-16 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US8608632B1 (en) | 2009-07-03 | 2013-12-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye |
| US9873001B2 (en) | 2008-01-07 | 2018-01-23 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| EP2227257B1 (en) * | 2008-01-07 | 2013-06-26 | Salutaris Medical Devices, Inc. | Devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye |
| US8602959B1 (en) | 2010-05-21 | 2013-12-10 | Robert Park | Methods and devices for delivery of radiation to the posterior portion of the eye |
| KR20180122484A (ko) * | 2008-11-04 | 2018-11-12 | 인리젠 | 세포-지지체 구조물 |
| USD691268S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691270S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691267S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691269S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| EP2496304A4 (en) * | 2009-11-02 | 2013-04-17 | Salutaris Medical Devices Inc | METHOD AND DEVICES FOR THE ADMINISTRATION OF MINIMALLY INVASIVE EXTRACOLAR RADIATION |
| US20110224800A1 (en) * | 2010-03-09 | 2011-09-15 | Ludlow John W | Cell-scaffold constructs |
| CA3025090A1 (en) * | 2010-05-03 | 2011-11-10 | Inregen | Smooth muscle cell constructs |
| TWI607757B (zh) | 2010-11-10 | 2017-12-11 | 英瑞金公司 | 治療製劑 |
| WO2012094611A1 (en) | 2011-01-06 | 2012-07-12 | Humacyte | Tissue-engineered constructs |
| JP6258224B2 (ja) * | 2012-01-31 | 2018-01-10 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | 工学的構造物の神経支配 |
| US11311367B2 (en) | 2012-01-31 | 2022-04-26 | Wake Forest University Health Sciences | Tissue-engineered gut-sphincter complexes and methods of making the same |
| US20130317315A1 (en) * | 2012-05-22 | 2013-11-28 | Tony V. Lu | Method of age management |
| US20130317622A1 (en) * | 2012-05-25 | 2013-11-28 | Antonio Sambusseti | Surgical method for grafting an artificial implant in a bladder and/or in a urethral or ureteral segment |
| NZ707873A (en) | 2012-10-24 | 2019-01-25 | Inregen | Renal cell populations and uses thereof |
| US10028857B2 (en) * | 2013-02-15 | 2018-07-24 | Convatec Technologies Inc | Methods and systems for ostomy care |
| CN103393482B (zh) * | 2013-08-14 | 2016-04-06 | 北京瑞健高科生物科技有限公司 | 一种基于组织基质材料的乳房假体支撑装置及其制备方法 |
| ITMI20131716A1 (it) | 2013-10-16 | 2015-04-17 | Antonio Sambusseti | Supporto tubolare assorbibile per patch tubolare destinato alla ricostruzione tissutale di segmenti uretrali e/o ureterali asportati |
| GB201322869D0 (en) * | 2013-12-23 | 2014-02-12 | Ucl Business Plc | Therapeutic agents and delivery with microspheres |
| US9861726B2 (en) | 2014-09-15 | 2018-01-09 | Covidien Lp | Coupling a body conduit to tissue |
| US10709807B2 (en) * | 2014-10-01 | 2020-07-14 | 3M Innovative Properties Company | Porous devices, kits, and methods for debridement |
| SG11201707686PA (en) * | 2015-03-19 | 2017-10-30 | Univ Nanyang Tech | A stent assembly and method of preparing the stent assembly |
| US20170051016A1 (en) | 2015-08-17 | 2017-02-23 | Northwestern University | Anti-inflammatory nanofibers |
| EP3357996B1 (en) * | 2015-09-29 | 2021-12-29 | Kaneka Corporation | Biological tissue fabrication information generating device, biological tissue fabrication system, and medical expense calculation system |
| US20190015190A1 (en) | 2015-12-30 | 2019-01-17 | Wake Forest University Health Sciences | Tissue-engineered gut-sphincter complexes and methods of making the same |
| RU2633309C2 (ru) * | 2016-02-25 | 2017-10-11 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО Тверской ГМУ Минздрава России) | Комбинированный хирургический дренаж |
| USD814637S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814638S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD815285S1 (en) | 2016-05-11 | 2018-04-10 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| US10548977B1 (en) | 2016-05-20 | 2020-02-04 | Emery Korpas | Pain relief utilizing a combination of polymer based materials |
| US10702704B2 (en) | 2016-05-20 | 2020-07-07 | E.K. Licensing, Llc | Pain relief utilizing polymer based materials or a combination of LED bulbs, polymer based materials and a near field accelerator |
| USD808529S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| USD808528S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| WO2018213659A1 (en) * | 2017-05-19 | 2018-11-22 | Gettman Matthew T | Methods and materials for treating urinary calculi |
| US11443433B2 (en) * | 2018-02-10 | 2022-09-13 | The Trustees Of The University Of Pennsylvania | Quantification and staging of body-wide tissue composition and of abnormal states on medical images via automatic anatomy recognition |
| WO2020010292A1 (en) | 2018-07-06 | 2020-01-09 | Neal Fearnot | Storage devices, loading devices, delivery systems kits, and associated methods |
| CN110448730A (zh) * | 2019-08-29 | 2019-11-15 | 上海白衣缘生物工程有限公司 | 一种用于鼓膜修复的生物补片及其制备方法 |
| GB2601793B (en) * | 2020-12-10 | 2025-07-23 | The Francis Crick Institute Ltd | Thymic constructs and uses thereof |
| CN113750297B (zh) * | 2021-09-03 | 2022-04-15 | 东华大学 | 一种结构和功能仿生尿道支架及其制备方法 |
| US20230132318A1 (en) * | 2021-10-25 | 2023-04-27 | Satellite Biosciences, Inc. | Methods of implanting engineered tissue constructs |
| CN114848898B (zh) * | 2022-06-23 | 2023-07-21 | 点云生物(杭州)有限公司 | 一种基于3d打印工艺制造的人工骨支架及方法 |
| WO2024044371A2 (en) * | 2022-08-26 | 2024-02-29 | The Texas A&M University System | Tubular structures, methods, and apparatuses for making and using the same |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4182339A (en) * | 1978-05-17 | 1980-01-08 | Hardy Thomas G Jr | Anastomotic device and method |
| US4217664A (en) * | 1979-02-02 | 1980-08-19 | Faso Joseph M | Prosthesis and method for creating a stoma |
| US4520821A (en) * | 1982-04-30 | 1985-06-04 | The Regents Of The University Of California | Growing of long-term biological tissue correction structures in vivo |
| US5863531A (en) * | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
| US5759830A (en) * | 1986-11-20 | 1998-06-02 | Massachusetts Institute Of Technology | Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo |
| CA1340581C (en) * | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5567612A (en) * | 1986-11-20 | 1996-10-22 | Massachusetts Institute Of Technology | Genitourinary cell-matrix structure for implantation into a human and a method of making |
| AU2900792A (en) * | 1991-10-24 | 1993-05-21 | Children's Medical Center Corporation | Neomorphogenesis of urological structures in vivo from cell culture |
| US6283761B1 (en) | 1992-09-08 | 2001-09-04 | Raymond Anthony Joao | Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information |
| US5514378A (en) * | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5399352A (en) * | 1993-04-14 | 1995-03-21 | Emory University | Device for local drug delivery and methods for using the same |
| US6039749A (en) * | 1994-02-10 | 2000-03-21 | Endovascular Systems, Inc. | Method and apparatus for deploying non-circular stents and graftstent complexes |
| US20020055786A1 (en) * | 1994-08-16 | 2002-05-09 | Anthony Atala | Reconstruction of urological structures with polymeric matrices |
| US5654273A (en) | 1994-09-22 | 1997-08-05 | Children's Medical Center Corporation | Synducin mediated modulation of tissue repair |
| US5618718A (en) | 1994-12-30 | 1997-04-08 | Universite Laval | Production of a contractile smooth muscle |
| US5586438A (en) * | 1995-03-27 | 1996-12-24 | Organ, Inc. | Portable device for preserving organs by static storage or perfusion |
| WO1996031232A1 (en) * | 1995-04-07 | 1996-10-10 | Purdue Research Foundation | Tissue graft and method for urinary bladder reconstruction |
| US5855610A (en) * | 1995-05-19 | 1999-01-05 | Children's Medical Center Corporation | Engineering of strong, pliable tissues |
| US6090618A (en) * | 1996-10-07 | 2000-07-18 | Arch Development Corporation | DNA constructs and viral vectors comprising a smooth muscle promoter |
| US5714359A (en) | 1995-10-12 | 1998-02-03 | The University Of Akron | Apparatus and method for electrostatic endothelial cell seeding in a vascular prosthesis |
| US6171344B1 (en) * | 1996-08-16 | 2001-01-09 | Children's Medical Center Corporation | Bladder submucosa seeded with cells for tissue reconstruction |
| US5902336A (en) * | 1996-10-15 | 1999-05-11 | Mirimedical, Inc. | Implantable device and method for removing fluids from the blood of a patient method for implanting such a device and method for treating a patient experiencing renal failure |
| WO1998025546A1 (en) * | 1996-12-10 | 1998-06-18 | Cook Biotech, Inc. | Tubular grafts from purified submucosa |
| FR2759575B1 (fr) | 1997-02-14 | 1999-04-30 | Assist Publ Hopitaux De Paris | Implant artificiel destine au remplacement de l'appareil excreteur urinaire chez l'etre humain |
| EP2075015B1 (en) | 1997-07-03 | 2015-03-11 | Massachusetts Institute of Technology | Tissue-engineered constructs |
| GB2333815B (en) * | 1997-08-26 | 2002-08-07 | Luk Getriebe Systeme Gmbh | A pressure medium control device |
| AU747166B2 (en) * | 1997-10-31 | 2002-05-09 | Children's Medical Center Corporation | Bladder reconstruction |
| WO1999025396A2 (en) | 1997-11-17 | 1999-05-27 | The Regents Of The University Of Michigan | Hybrid tissues for tissue engineering |
| US6371992B1 (en) * | 1997-12-19 | 2002-04-16 | The Regents Of The University Of California | Acellular matrix grafts: preparation and use |
| US20030082152A1 (en) | 1999-03-10 | 2003-05-01 | Hedrick Marc H. | Adipose-derived stem cells and lattices |
| DE19912472B4 (de) * | 1999-03-18 | 2011-03-17 | Wassermann, Helmut, Prof. | Künstliches Harnableitungssystem |
| US7131996B2 (en) * | 1999-03-18 | 2006-11-07 | Helmut Wasserman | Artificial urinary diversion device |
| US6709465B2 (en) * | 1999-03-18 | 2004-03-23 | Fossa Medical, Inc. | Radially expanding ureteral device |
| US6503273B1 (en) | 1999-11-22 | 2003-01-07 | Cyograft Tissue Engineering, Inc. | Tissue engineered blood vessels and methods and apparatus for their manufacture |
| US6432712B1 (en) * | 1999-11-22 | 2002-08-13 | Bioscience Consultants, Llc | Transplantable recellularized and reendothelialized vascular tissue graft |
| US6428802B1 (en) * | 1999-12-29 | 2002-08-06 | Children's Medical Center Corp. | Preparing artificial organs by forming polylayers of different cell populations on a substrate |
| US6376244B1 (en) * | 1999-12-29 | 2002-04-23 | Children's Medical Center Corporation | Methods and compositions for organ decellularization |
| US6866686B2 (en) * | 2000-01-28 | 2005-03-15 | Cryolife, Inc. | Tissue graft |
| AT411328B (de) * | 2000-07-12 | 2003-12-29 | Universitaetsklinikum Freiburg | Röhrensystem zur rekonstruktion einer harnröhre |
| KR20020094074A (ko) * | 2001-06-07 | 2002-12-18 | (주)에이치비메디컬스 | 체내 이식관 |
| CN1684589A (zh) * | 2002-05-02 | 2005-10-19 | 普渡研究基金会 | 血管化增强的移植构造物 |
| US7299805B2 (en) * | 2002-06-07 | 2007-11-27 | Marctec, Llc | Scaffold and method for implanting cells |
| US20040029266A1 (en) * | 2002-08-09 | 2004-02-12 | Emilio Barbera-Guillem | Cell and tissue culture device |
| CN1194653C (zh) * | 2002-12-30 | 2005-03-30 | 中国中医研究院西苑医院 | 具有防治再狭窄药物涂层的体内腔管内支架及其制造方法 |
| US7182745B2 (en) * | 2003-03-25 | 2007-02-27 | Boston Scientific Scimed, Inc. | Retaining stent |
| GB0402103D0 (en) * | 2004-02-02 | 2004-03-03 | Hengelmolen Rudy | Tubular graft |
| DE602005023592D1 (de) | 2004-03-09 | 2010-10-28 | Absorber Ab | Endothelvorläuferzellen und verfahren zur verwendung davon |
| JP5755395B2 (ja) * | 2004-03-10 | 2015-07-29 | オーバスネイチ メディカル、インコーポレイテッド | 薬剤溶出式の植設可能な医療デバイスによる前駆内皮細胞の捕捉方法 |
| US8425539B2 (en) * | 2004-04-12 | 2013-04-23 | Xlumena, Inc. | Luminal structure anchoring devices and methods |
| US8512219B2 (en) * | 2004-04-19 | 2013-08-20 | The Invention Science Fund I, Llc | Bioelectromagnetic interface system |
| US7935096B2 (en) * | 2004-09-06 | 2011-05-03 | Ostomycure As | Percutaneous implant |
| US20060199265A1 (en) * | 2005-03-02 | 2006-09-07 | Wolf Michael F | Seeding implantable medical devices with cells |
| US7531503B2 (en) * | 2005-03-11 | 2009-05-12 | Wake Forest University Health Sciences | Cell scaffold matrices with incorporated therapeutic agents |
| US20080109058A1 (en) * | 2005-06-01 | 2008-05-08 | Cook Incorporated | Intraoperative Anastomosis Method |
| WO2007001992A2 (en) * | 2005-06-21 | 2007-01-04 | Regents Of The University Of Minnesota | Ureteral stent with axial and radial variability |
| US7531355B2 (en) | 2005-07-29 | 2009-05-12 | The Regents Of The University Of California | Methods and compositions for smooth muscle reconstruction |
| FR2890977A1 (fr) * | 2005-09-19 | 2007-03-23 | Assist Publ Hopitaux De Paris | Procede d'obtention de cellules musculaires lisses humaines et leurs applications |
| ITMI20051854A1 (it) * | 2005-10-03 | 2007-04-04 | Sambusseti Antonio | Patch per la sostituzione di una porzione di parete vescicale a seguito di vescitectomia parziale |
| JP4644786B2 (ja) * | 2005-10-18 | 2011-03-02 | 国立大学法人 東京医科歯科大学 | マイクロビーズの製造方法 |
| US7918897B2 (en) * | 2006-02-10 | 2011-04-05 | Tengion, Inc. | Scaffolds for organ reconstruction and augmentation |
| US20070275363A1 (en) | 2006-02-10 | 2007-11-29 | Bertram Timothy A | Bioreactor for organ reconstruction and augmentation |
| US20080081323A1 (en) * | 2006-09-29 | 2008-04-03 | Daniel Keeley | Regenerative Medicine Devices and Melt-Blown Methods of Manufacture |
| US20110035023A1 (en) * | 2007-08-31 | 2011-02-10 | Veronique Maquet | Prosthesis for promoting the in vivo reconstruction of a hollow organ or a portion of a hollow organ |
| US8992409B2 (en) * | 2007-10-11 | 2015-03-31 | Peter Forsell | Method for controlling flow in a bodily organ |
| CN101147810B (zh) * | 2007-11-01 | 2010-05-19 | 南昌大学第一附属医院 | 细胞-生物可降解材料复合物及其制备方法和应用 |
| WO2009064353A1 (en) * | 2007-11-13 | 2009-05-22 | Cook Incorporated | Intraluminal bypass prosthesis |
| US20090254039A1 (en) * | 2007-12-21 | 2009-10-08 | O'brien Nicole Sams | Designer accessory for use with an intracorporeal medical device |
| KR20180122484A (ko) * | 2008-11-04 | 2018-11-12 | 인리젠 | 세포-지지체 구조물 |
| US8192500B2 (en) * | 2008-12-12 | 2012-06-05 | Boston Scientific Scimed, Inc. | Ureteral stent |
| WO2010087769A1 (en) * | 2009-01-29 | 2010-08-05 | Milux Holding S.A | Implant comprising an expandable section |
| US8900116B2 (en) * | 2009-07-14 | 2014-12-02 | Stimatix Gi Ltd. | Inflatable stomal implant |
| CA3025090A1 (en) * | 2010-05-03 | 2011-11-10 | Inregen | Smooth muscle cell constructs |
| US8790322B2 (en) * | 2010-08-03 | 2014-07-29 | King Saud University | Stoma coat |
| WO2012054522A2 (en) * | 2010-10-19 | 2012-04-26 | Allergan, Inc. | Anchored non-piercing duodenal sleeve and delivery systems |
-
2009
- 2009-11-04 KR KR1020187031781A patent/KR20180122484A/ko not_active Ceased
- 2009-11-04 WO PCT/US2009/063306 patent/WO2010054013A2/en not_active Ceased
- 2009-11-04 KR KR1020117012781A patent/KR101724639B1/ko not_active Expired - Fee Related
- 2009-11-04 CN CN201410270167.XA patent/CN104274256A/zh active Pending
- 2009-11-04 PL PL09753285T patent/PL2352529T3/pl unknown
- 2009-11-04 JP JP2011534906A patent/JP6124041B2/ja active Active
- 2009-11-04 CN CN200980153634.8A patent/CN102271722B/zh not_active Expired - Fee Related
- 2009-11-04 PT PT09753285T patent/PT2352529T/pt unknown
- 2009-11-04 EP EP18175242.9A patent/EP3461507A1/en not_active Withdrawn
- 2009-11-04 NZ NZ59320809A patent/NZ593208A/xx not_active IP Right Cessation
- 2009-11-04 CA CA2742599A patent/CA2742599A1/en not_active Abandoned
- 2009-11-04 AU AU2009313554A patent/AU2009313554B2/en not_active Ceased
- 2009-11-04 EP EP09753285.7A patent/EP2352529B1/en active Active
- 2009-11-04 NZ NZ60429609A patent/NZ604296A/en not_active IP Right Cessation
- 2009-11-04 NZ NZ626419A patent/NZ626419A/en not_active IP Right Cessation
- 2009-11-04 KR KR1020197016239A patent/KR20190067267A/ko not_active Ceased
- 2009-11-04 KR KR1020177009069A patent/KR20170041279A/ko not_active Ceased
- 2009-11-04 US US12/612,606 patent/US8337485B2/en not_active Expired - Fee Related
- 2009-11-04 ES ES09753285T patent/ES2689932T3/es active Active
- 2009-11-04 KR KR1020187008826A patent/KR20180034707A/ko not_active Ceased
-
2012
- 2012-11-20 US US13/682,614 patent/US9271824B2/en not_active Expired - Fee Related
-
2014
- 2014-06-20 JP JP2014127197A patent/JP6121948B2/ja active Active
-
2015
- 2015-07-14 HK HK15106716.3A patent/HK1205923A1/xx unknown
-
2017
- 2017-03-29 JP JP2017065065A patent/JP2017159048A/ja active Pending
- 2017-05-18 US US15/599,137 patent/US20180071074A1/en not_active Abandoned
-
2018
- 2018-10-24 JP JP2018200327A patent/JP2019048094A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101724639B1 (ko) | 세포-지지체 구조물 | |
| JP2012510302A5 (cg-RX-API-DMAC7.html) | ||
| EP2566529B1 (en) | Smooth muscle cell constructs | |
| KR20130005285A (ko) | 세포 골격 구조물 | |
| CA3037457A1 (en) | Cell-scaffold constructs | |
| AU2019202548A1 (en) | Cell-scaffold constructs | |
| HK1159529B (en) | Cell-scaffold constructs | |
| HK1159529A (en) | Cell-scaffold constructs | |
| HK1232810A1 (en) | Smooth muscle cell constructs | |
| HK1182652B (en) | Smooth muscle cell constructs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20181101 Application number text: 1020187008826 Filing date: 20180328 |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20181130 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20181205 Patent event code: PE09021S01D |
|
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20190605 Application number text: 1020187008826 Filing date: 20180328 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20190610 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20181205 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |